Page last updated: 2024-11-07

n-monodemethyldiltiazem

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-monodemethyldiltiazem: RN given refers to (cis)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID107891
CHEMBL ID3350581
CHEBI ID169303
SCHEMBL ID12592499
MeSH IDM0149823

Synonyms (26)

Synonym
[(2s,3s)-2-(4-methoxyphenyl)-5-[2-(methylamino)ethyl]-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate
85100-17-0
n-desmethyldiltiazem
CHEBI:169303
n-demethyldiltiazem
86408-45-9
1,5-benzothiazepin-4(5h)-one, 3-(acetyloxy)-2,3-dihydro-2-(4-methoxyphenyl)-5-(2-(methylamino)ethyl)-, (2s,3s)-
unii-if0841k5lk
if0841k5lk ,
cis-3-(acetyloxy)-2,3-dihydro-2-(4-methoxyphenyl)-5-(2-(methylamino)ethyl)-1,5-benzothiazepin-4(5h)-one
1,5-benzothiazepin-4(5h)-one, 3-(acetyloxy)-2,3-dihydro-2-(4-methoxyphenyl)-5-(2-(methylamino)ethyl)-, cis-
n-monodemethyldiltiazem
DTXSID40234221
SCHEMBL12592499
(2s,3s)-2-(4-methoxyphenyl)-5-(2-(methylamino) ethyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate
1,5-benzothiazepin-4(5h)-one, 3-(acetyloxy)-2,3-dihydro-2-(4-methoxyphenyl)-5-(2-(methylamino)ethyl)-, (2s-cis)-
diltiazem hydrochloride impurity d [ep impurity]
CHEMBL3350581
AKOS030242881
DTXSID60873797
diltiazem ep impurity d; n-desmethyl diltiazem
(2s,3s)-2-(4-methoxyphenyl)-5-[2-(methylamino)ethyl]-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate; (2s-cis)-3-(acetyloxy)-2,3-dihydro-2-(4-methoxyphenyl)-5-[2-(methylamino)ethyl]-1,5-benzothiazepin-4(5h)-one monohydrochloride; n-demethyldiltia
Q27280692
cis-2-(4-methoxyphenyl)-5-(2-(methylamino)ethyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate
n-desmethyl diltiazem (hydrochloride)
(2s,3s)-2-(4-methoxyphenyl)-5-(2-(methylamino)ethyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Elimination half-life increases and gives AUC's and Cmax higher than those predicted from single dose data."( Diltiazem pharmacokinetics in elderly volunteers after single and multiple doses.
Boucher, S; Caillé, G; Grace, MG; Lakhani, Z; Russell, A; Spénard, J; Thiffault, J,
)
0.13
" These findings suggest that some form of acute tolerance to the electrophysiologic effect of diltiazem develops, but the results of pharmacodynamic modeling suggest that this is not caused by the antagonistic effects the metabolites."( The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose.
Boyd, RA; Chin, SK; Don-Pedro, O; Giacomini, KM; Sheiner, LB; Verotta, D; Williams, RL, 1989
)
0.28
" The half-life of the metabolite N-demethyldiltiazem (MA) was similar to that of diltiazem, whereas the half-lives of deacetyldiltiazem (M1) and N-demethyldeacetyldiltiazem (M2) were longer."( Pharmacokinetics of diltiazem and its metabolites after repeated multiple-dose treatments in healthy volunteers.
Höglund, P; Nilsson, LG, 1989
)
0.28
" The half-life of the metabolite N-demethyldiltiazem was similar to that of diltiazem whereas the half-lives of the metabolites deacetyldiltiazem and N-demethyldeacetyldiltiazem were longer."( Pharmacokinetics of diltiazem and its metabolites after single and multiple dosing in healthy volunteers.
Höglund, P; Nilsson, LG, 1989
)
0.28
" The slope of the alpha- and beta-phases increased slightly in six of the eight pregnant rabbits as compared with the non-pregnant animal, but the other pharmacokinetic parameters that largely determine drug disposition (AUC, V(n), CL) showed no significant differences."( Diltiazem blood pharmacokinetics in the pregnant and non-pregnant rabbit: maternal and foetal tissue levels.
Aramayona, JJ; Bregante, MA; Fraile, LJ; Garcia, MA; Solans, C, 2000
)
0.31
" Semiphysiologically based pharmacokinetic (PBPK) models were developed for DTZ and MDZ with the major metabolite of DTZ, N-desmethyldiltiazem (nd-DTZ), incorporated in the DTZ model."( Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite.
Gorski, JC; Hall, SD; Jones, DR; Quinney, SK; Zhang, X, 2009
)
0.35

Bioavailability

ExcerptReferenceRelevance
"The influence of food on the bioavailability of a conventional tablet and of a slow-release capsule of diltiazem was investigated in two separate groups of 24 healthy volunteers in two open crossover studies."( Influence of food on the bioavailability of diltiazem and two of its metabolites following the administration of conventional tablets and slow-release capsules.
Boucher, S; Caillé, G; Du Souich, P; Lery, L; Lery, N; Pilon, D; Spenard, J; Varin, F; Vezina, M, 1990
)
0.28
" The area under the curve of diltiazem in a dosing interval at steady state increased significantly compared with the single dose, indicating an increased bioavailability after repeated dosing, probably because of decreased presystemic elimination."( Pharmacokinetics of diltiazem and its metabolites after single and multiple dosing in healthy volunteers.
Höglund, P; Nilsson, LG, 1989
)
0.28
"The objective of the presented two-way randomized crossover study was to investigate whether repeated doses of grapefruit juice (200 ml at 0, 2, 4, 8 and 12 h) enhanced bioavailability of diltiazem (120 mg, orally) in nine healthy male subjects."( Lack of effect of grapefruit juice on diltiazem bioavailability in normal subjects.
Henschel, L; Hoffmann, A; Kraul, H; Merkel, U; Sigusch, H, 1994
)
0.29
"Since the ability of the small intestine to biotransform a drug may decrease in distal segments of the intestine, this study aimed to assess whether the site of administration in the small intestine could affect the systemic bioavailability of diltiazem and its two active metabolites, N-desmethyldiltiazem (MA) and desacetyl-diltiazem (M1)."( The site of absorption in the small intestine determines diltiazem bioavailability in the rabbit.
Caillé, G; du Souich, P; Homsy, W, 1995
)
0.29
"The site of absorption into the intestine modulates the bioavailability of diltiazem and its two active metabolites."( The site of absorption in the small intestine determines diltiazem bioavailability in the rabbit.
Caillé, G; du Souich, P; Homsy, W, 1995
)
0.29

Dosage Studied

ExcerptRelevanceReference
" Chronic oral dosing significantly lowered both the systemic and oral clearance of diltiazem, with no changes in either the volume of distribution or blood binding of diltiazem."( The effects of chronic oral diltiazem and cimetidine dosing on the pharmacokinetics and negative dromotropic action of intravenous and oral diltiazem in the dog.
Bai, SA; Lankford, S; Maskasame, C, 1992
)
0.28
" The area under the curve of diltiazem in a dosing interval at steady state increased significantly compared with the single dose, indicating an increased bioavailability after repeated dosing, probably because of decreased presystemic elimination."( Pharmacokinetics of diltiazem and its metabolites after single and multiple dosing in healthy volunteers.
Höglund, P; Nilsson, LG, 1989
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzothiazepine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID589126Mechanism based inhibition of human cytochrome P450 3A4 measured by midazolam hydroxylase activity2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID1222758Fraction unbound in human treated with dilitiazem at 120 mg, po2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Which metabolites circulate?
AID1222756Unbound hepatobiliary clearance in human treated with dilitiazem at 120 mg, po2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Which metabolites circulate?
AID1222757Systemic clearance in human treated with dilitiazem at 120 mg, po2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Which metabolites circulate?
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (25.93)18.7374
1990's13 (48.15)18.2507
2000's5 (18.52)29.6817
2010's2 (7.41)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.83

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.83 (24.57)
Research Supply Index3.53 (2.92)
Research Growth Index4.35 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.83)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (10.00%)5.53%
Reviews1 (3.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (86.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]